Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Celanese
CE
$4.86B
| $40M | 0.05% |
421,800
+65,800
| +18% | +$5.86M |
|
477
Ball Corp
BALL
$16.4B
| $40M | 0.05% |
948,522
-755,300
| -44% | -$29.8M |
|
|
PARA
478
DELISTED
Paramount Global Class B
PARA
| $39.9M | 0.05% |
+625,500
| New | +$40M |
|
479
Medifast
MED
$128M
| $39.6M | 0.05% |
956,100
+2,100
| +0.2% | +$91.3K |
|
|
ISBC
480
DELISTED
Investors Bancorp, Inc.
ISBC
| $39.2M | 0.05% |
2,931,325
-31,400
| -1% | -$430K |
|
481
Burlington
BURL
$22.4B
| $39M | 0.05% |
423,600
-152,200
| -26% | -$14.6M |
|
|
LMNX
482
DELISTED
Luminex Corp
LMNX
| $38.9M | 0.05% |
1,841,540
+252,299
| +16% | +$5.05M |
|
483
Ingredion
INGR
$6.63B
| $38.8M | 0.05% |
325,500
+198,100
| +155% | +$23.5M |
|
484
Moody's
MCO
$84.6B
| $38.7M | 0.05% |
317,700
-400,400
| -56% | -$46.9M |
|
485
Medtronic
MDT
$116B
| $38.5M | 0.05% |
+434,000
| New | +$36.6M |
|
486
Sempra
SRE
$56.5B
| $38.4M | 0.05% |
680,400
-1,698,800
| -71% | -$96.1M |
|
|
MXIM
487
DELISTED
Maxim Integrated Products
MXIM
| $38.4M | 0.05% |
854,300
-485,900
| -36% | -$22.3M |
|
488
EXL Service
EXLS
$5.36B
| $38.4M | 0.05% |
3,450,500
+18,500
| +0.5% | +$187K |
|
489
National Bank Holdings
NBHC
$1.94B
| $38.2M | 0.05% |
1,154,900
+10,600
| +0.9% | +$337K |
|
490
RE/MAX Holdings
RMAX
$265M
| $38.2M | 0.05% |
681,900
+36,400
| +6% | +$2.05M |
|
491
Quad
QUAD
$506M
| $38.2M | 0.05% |
1,666,500
-149,300
| -8% | -$3.55M |
|
492
American States Water
AWR
$3.52B
| $38.2M | 0.05% |
805,000
-44,300
| -5% | -$2.04M |
|
493
Gerdau
GGB
$9.42B
| $38.1M | 0.05% |
15,728,327
-778,680
| -5% | -$1.84M |
|
|
IMOS
494
ChipMOS TECHNOLOGIES
IMOS
$2.01B
| $38M | 0.05% |
1,631,938
-76,579
| -4% | -$1.71M |
|
495
Delta Air Lines
DAL
$60B
| $37.9M | 0.05% |
706,100
-166,200
| -19% | -$8.14M |
|
|
ATRI
496
DELISTED
Atrion Corp
ATRI
| $37.8M | 0.05% |
58,834
+18,633
| +46% | +$10M |
|
|
CS
497
DELISTED
Credit Suisse Group
CS
| $37.8M | 0.05% |
2,589,188
-492,856
| -16% | -$7.11M |
|
498
Regions Financial
RF
$27B
| $37.7M | 0.05% |
2,577,721
-1,285,500
| -33% | -$18.1M |
|
|
AJRD
499
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $37.6M | 0.05% |
1,809,895
+51,600
| +3% | +$1.11M |
|
|
TMHC
500
DELISTED
Taylor Morrison
TMHC
| $37.6M | 0.05% |
1,565,100
+955,000
| +157% | +$22M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.